ProCE Banner Events

Share

Advances in BTK Inhibitor Therapy for B-Cell Lymphomas: Expert Discussion and Resources to Elevate Patient Care

Join us at this live webinar for expert discussions and takeaways on the role of BTK inhibitors for patients with B-cell lymphomas.

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Who Should Attend

This program is intended for hematology/oncology nurses, physician associates, and other healthcare professionals caring for patients with B-cell lymphomas.

Time and location

Saturday, November 16, 2024

8:10 AM - 9:10 AM Eastern Time (ET)

Virtual

Faculty
Emily Patterson, AGACNP-BC

Massachusetts General Hospital
Lymphoma Clinic
Boston, Massachusetts

Agenda

Introduction and ARS Questions

BTK Inhibitors in 2024: What Nurses Need to Know

  •  Mechanism of BTK inhibitors in B-cell lymphoma
  •  Current indications for BTK inhibitors

Clinical Application: Educating Patients With B-Cell Lymphomas on the Rationale for Using BTK Inhibitors and Their Benefits and Risks

Nursing Strategies to Manage BTK inhibitor–Associated Adverse Events

  • How can oncology nurses anticipate, identify, and manage treatment-related AEs, especially considering the unique AE profiles of BTK inhibitors

Clinical Application: Implementing Strategies and Education to Keep Patients Adherent to Their Prescribed BTK Inhibitor

  • Understanding adherence (taking oral medication as prescribed) and persistence (remaining on oral therapy for the intended duration of treatment)
  • Repercussions of poor adherence or overadherence

Closing Remarks and Question and Answer Session

CME/CE Info

Goal Statement
This activity aims to improve the knowledge, confidence, and competence of hematology/oncology nurses to understand and optimally apply available clinical data to nursing practice on BTK inhibitors in the treatment of B-cell lymphomas in order to improve patient care. 

Target Audience
This program is intended for hematology/oncology nurses, physician associates, and other healthcare professionals caring for patients with B-cell lymphomas.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Explain differences in BTK inhibitors to patients with B-cell lymphomas, including current and emerging indications, safety, and treatment resistance
  • Develop strategies to maintain adherence and persistence to prescribed BTK inhibitor regimens for patients with B-cell lymphomas
  • Manage and mitigate adverse events associated with BTK inhibitor therapy in patients with B-cell lymphomas
  • Counsel patients with B-cell malignancies on ongoing clinical trial opportunities with BTK inhibitor therapy to ensure inclusive enrollment opportunities and equitable care

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC.

Supported by an educational grant from BeiGene.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.